Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) EPS (Basic) (2023 - 2025)

Mangoceuticals (MGRX) has disclosed EPS (Basic) for 3 consecutive years, with -$0.01 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 98.08% to -$0.01 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.56 through Dec 2025, up 43.49% year-over-year, with the annual reading at -$2.17 for FY2025, 54.79% up from the prior year.
  • EPS (Basic) hit -$0.01 in Q4 2025 for Mangoceuticals, up from -$0.69 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.01 in Q4 2025 to a low of -$1.9 in Q4 2023.
  • Historically, EPS (Basic) has averaged -$0.92 across 3 years, with a median of -$0.91 in 2024.
  • Biggest five-year swings in EPS (Basic): tumbled 878.57% in 2024 and later soared 98.08% in 2025.
  • Year by year, EPS (Basic) stood at -$1.9 in 2023, then skyrocketed by 72.63% to -$0.52 in 2024, then skyrocketed by 98.08% to -$0.01 in 2025.
  • Business Quant data shows EPS (Basic) for MGRX at -$0.01 in Q4 2025, -$0.69 in Q3 2025, and -$0.57 in Q2 2025.